CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: Application for MRD detection in leukemia patients

Department of Pathology, Karolinska University Hospital, Solna and Karolinska Institute, 171 76, Stockholm, Sweden.
International journal of hematology (Impact Factor: 1.92). 08/2009; 90(3):292-302. DOI: 10.1007/s12185-009-0389-z
Source: PubMed


Fast development in polychromatic flow cytometry (PFC) makes it possible to study CD34+ cells with two scatter and eight fluorescence parameters. Minimal residual disease (MRD) is determined as persistence of leukemic cells at submicroscopic levels in bone marrow (BM) of patients in complete remission. MRD can be present in collections of hematopoietic stem cell from blood (HSC-B). Using PFC, we have defined patterns of antigen expression in CD34+ cell subpopulations in BM and applied them as templates in MRD analysis. Twelve BM samples from hospital control (HC) patients with no signs of hematological malignancy were studied using five 8-color monoclonal antibody combinations detecting subsets of CD34+ cells. These patterns have been used as templates to determine levels of MRD in HSC-B collections from six AML patients. Several subsets of CD34+ precursor cells were found to be present at very low frequencies (<10(-4)) in BM and/or HSC-B collections. All six HSC-B collections from AML patients showed MRD by 8-color technique and only three by previously applied 3-color method. The 8-color technique showed promising results in efficient detection of different CD34+ subpopulations of HSC-B and in MRD quantification. Monitoring of MRD should become a part of quality control of HSC-B collections.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective and subjective measures were obtained for a 4-band, 16-kbit/s sub-band coder utilizing adaptive quantizers with fixed and dynamic bit allocations. Objective measures indicated that block quantization (block companded PCM with a Gaussian probability density function, BCPCM-G) with dynamic bit allocation is slightly better than an adaptive differential PCM with a variable predictor (ADPCM-V) and fixed bit allocation, but outperforms ADPCM with a fixed predictor and fixed bit allocation (ADPCM-F) by 4-5 dB. Subjective measures, however, indicated that ADPCM-V has about 6-dB advantage over BCPCM-G. A comparison between ADPCM-V and ADPCM-F indicated that adaptive prediction provides a 4-5 dB objective gain and 16-dB subjective gain over fixed prediction. Further, all listeners preferred ADPCM-V over BCPCM-G and ADPCM-F, and 85% preferred BCPCM-G over ADPCM-F.
    No preview · Conference Paper · Jun 1982
  • [Show abstract] [Hide abstract]
    ABSTRACT: The last 15 years have witnessed significant improvements in technologies to detect minimal residual disease (MRD) in acute myeloid leukemia (AML). We review recent studies highlighting the potential for novel and standardized assays to provide independent prognostic information and develop more personalized treatment approaches. Progress includes establishment of optimized real-time quantitative PCR (RQ-PCR) assays for WT1 (commonly overexpressed and a putative therapeutic target) and mutant NPM1 genes. Moreover, sequential MRD monitoring using an internationally standardized PML-RARA RQ-PCR assay has been successfully used to guide molecularly targeted therapy in acute promyelocytic leukemia (APL). There have also been significant advances in multiparameter flow cytometry (MFC) to detect MRD, with introduction of 6-10 color technology and improved understanding of the immunophenotype of leukemic stem cells. Sensitive MRD detection using MFC and/or RQ-PCR has become feasible in virtually all AML patients. MRD monitoring is now considered a standard of care in APL. Recent studies provide a strong rationale for prospective trials investigating the merits of extending MRD detection to alter therapy and potentially improve outcome in other AML subtypes.
    No preview · Article · Nov 2010 · Current opinion in oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Applications of flow cytometry in pediatric cancers have expanded substantially in recent years. In acute leukemias, the commonest childhood cancer, flow cytometry can now define complex antigenic profiles that are associated with specific cytogenetic/molecular defects and can also directly identify BCR-ABL fusion protein. Flow cytometry based scoring system has been described for diagnosis of myelodysplastic syndromes. In solid tumors, flow cytometry was previously used mainly to determine DNA content for prognosis; however, recent studies in children with neuroblastoma and Ewing sarcoma have identified its diagnostic utility. In this review, we will discuss the current and future applications of flow cytometry in pediatric hematology-oncology.
    No preview · Article · Jul 2011 · Pediatric Blood & Cancer
Show more